Globus Medical (GMED) Expected to Announce Earnings on Thursday

Globus Medical (NYSE:GMED) is anticipated to post its Q3 2025 results after the market closes on Thursday, November 6th. Analysts expect Globus Medical to post earnings of $0.79 per share and revenue of $734.5760 million for the quarter. Individuals may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Thursday, November 6, 2025 at 4:30 PM ET.

Globus Medical (NYSE:GMED) last issued its quarterly earnings results on Thursday, August 7th. The medical device company reported $0.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.76 by $0.10. Globus Medical had a return on equity of 10.65% and a net margin of 13.58%.The company had revenue of $745.34 million for the quarter, compared to analysts’ expectations of $738.91 million. During the same period last year, the firm earned $0.75 EPS. The firm’s revenue for the quarter was up 18.4% on a year-over-year basis. On average, analysts expect Globus Medical to post $3 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Globus Medical Stock Performance

Shares of GMED stock opened at $61.77 on Wednesday. Globus Medical has a 1 year low of $51.79 and a 1 year high of $94.93. The stock has a market cap of $8.34 billion, a PE ratio of 23.76, a price-to-earnings-growth ratio of 1.68 and a beta of 1.12. The business’s fifty day moving average is $59.36 and its 200-day moving average is $59.88.

Insider Activity at Globus Medical

In other Globus Medical news, Director Ann D. Rhoads sold 10,000 shares of the firm’s stock in a transaction dated Monday, September 15th. The shares were sold at an average price of $58.46, for a total value of $584,600.00. Following the completion of the transaction, the director directly owned 25,384 shares in the company, valued at $1,483,948.64. This trade represents a 28.26% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. 18.51% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. EverSource Wealth Advisors LLC grew its stake in Globus Medical by 74.3% in the second quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock valued at $27,000 after purchasing an additional 197 shares in the last quarter. Corient Private Wealth LLC grew its stake in Globus Medical by 0.7% in the second quarter. Corient Private Wealth LLC now owns 46,737 shares of the medical device company’s stock valued at $2,756,000 after purchasing an additional 317 shares in the last quarter. Jones Financial Companies Lllp grew its stake in Globus Medical by 237.3% in the first quarter. Jones Financial Companies Lllp now owns 850 shares of the medical device company’s stock valued at $62,000 after purchasing an additional 598 shares in the last quarter. Headlands Technologies LLC grew its stake in Globus Medical by 485.4% in the second quarter. Headlands Technologies LLC now owns 761 shares of the medical device company’s stock valued at $45,000 after purchasing an additional 631 shares in the last quarter. Finally, Integrated Wealth Concepts LLC grew its stake in Globus Medical by 33.0% in the first quarter. Integrated Wealth Concepts LLC now owns 4,375 shares of the medical device company’s stock valued at $320,000 after purchasing an additional 1,085 shares in the last quarter. Hedge funds and other institutional investors own 95.16% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. Weiss Ratings reiterated a “hold (c)” rating on shares of Globus Medical in a research report on Wednesday, October 8th. Wall Street Zen cut Globus Medical from a “buy” rating to a “hold” rating in a report on Friday, September 26th. Canaccord Genuity Group decreased their target price on Globus Medical from $97.00 to $90.00 and set a “buy” rating on the stock in a report on Tuesday, July 22nd. Royal Bank Of Canada set a $88.00 target price on Globus Medical in a report on Friday, October 10th. Finally, Stifel Nicolaus assumed coverage on Globus Medical in a report on Tuesday, October 28th. They issued a “hold” rating and a $64.00 target price on the stock. Seven analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Globus Medical presently has an average rating of “Moderate Buy” and an average price target of $84.55.

About Globus Medical

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.